

**2021 No. 478**

**PUBLIC HEALTH**

**The Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Amendment (No. 13) Regulations 2021**

*Approved by the Scottish Parliament*

*Made - - - - 16th December 2021*

*Coming into force - - 17th December 2021*

*Laid before the Scottish Parliament at 9.30 a.m. on 17th December 2021*

The Scottish Ministers make the following Regulations in exercise of the powers conferred by sections 94(1)(b)(i) and 122(2) of the Public Health etc. (Scotland) Act 2008(a) and all other powers enabling them to do so.

In accordance with section 122(6) of that Act, the Scottish Ministers consider that these Regulations need to be made urgently, without a draft having been laid before, and approved by resolution of, the Scottish Parliament.

**Citation and Commencement**

1. These Regulations may be cited as the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Amendment (No. 13) Regulations 2021 and come into force on 17 December 2021.

**Amendment of the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Regulations 2021**

2. The Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Regulations 2021(b) are amended in accordance with regulations 3 to 13.

**Amendment of regulation 2**

3. In regulation 2 (interpretation: general)—

- (a) in the definition of “COVID-19 vaccination eligibility criteria”, for “paragraphs (2) to (7) of regulation 3”, substitute “regulations 3B to 3H”,
- (b) in the definition of “eligible vaccinated arrival”, for “regulation 3”, substitute “regulation 3A”,

---

(a) 2008 asp 5.

(b) S.S.I. 2021/322; amending instruments are S.S.I. 2021/328, 2021/343, 2021/350, 2021/357, 2021/359, 2021/382, 2021/425, 2021/440, 2021/441, 2021/443, 2021/454, 2021/455 and 2021/470.

(c) after the definition of “eligible vaccinated arrival” insert—

““EU Digital COVID Certificate” means a certificate of COVID-19 records issued by either a member state of the European Union, European Economic Area or the European Free Trade Association, or a European microstate,

“European microstate” means Andorra, Liechtenstein, Monaco, San Marino, the Sovereign Order of St John or the Vatican City State.”.

### **Amendment of regulation 3**

4. For regulation 3 (interpretation: eligible vaccinated arrivals), substitute—

## **“PART 1A**

### **Eligible vaccinated arrivals**

#### **Interpretation of Part**

3.—(1) In this Part—

“authorised vaccine” means a medicinal product for vaccination against coronavirus which—

(a) in relation to doses received in the United Kingdom, is authorised—

(i) for supply in the United Kingdom in accordance with a marketing authorisation, or

(ii) by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc.) of the Human Medicines Regulations 2012(a),

(b) in relation to doses received in a relevant country listed in the table in paragraph (2), is authorised for supply in that country following evaluation by the relevant regulator for that country,

(c) in relation to doses received in any other country or territory (including a relevant country listed in schedule 1A (relevant countries)), is authorised in the United Kingdom in accordance with head (i) or (ii) of paragraph (a),

“clinical trial” has the meaning given in regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2004 (interpretation)(b),

“Crown servant” has the meaning given in section 12(1)(a) to (e) of the Official Secrets Act 1989(c),

“government contractor” has the meaning given in section 12(2) of the Official Secrets Act 1989,

“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012,

---

(a) S.I. 2012/1916.

(b) S.I. 2004/1031.

(c) 1989 c. 6. Section 12 was amended by paragraph 22 of schedule 10 of the Reserve Forces Act 1996 (c. 14), by paragraph 30 of schedule 12 of the Government of Wales Act 1998 (c. 38), by paragraph 26 of schedule 8 of the Scotland Act 1998 (c. 46), by paragraph 9(3) of schedule 13 of the Northern Ireland Act 1998 (c. 47), by paragraph 9 of schedule 6 of the Police (Northern Ireland) Act 2000 (c. 32), by paragraph 6 of schedule 14 of the Energy Act 2004 (c. 20), by paragraph 58 of schedule 4 of the Serious Organised Crime and Police Act 2005, by paragraph 34 of schedule 10, and paragraph 1 of schedule 12, of the Government of Wales Act 2006 (c. 32), and by paragraph 36 of schedule 8 of the Crime and Courts Act 2013 (c. 22).

“marketing authorisation”—

- (a) in relation to a vaccine authorised for supply in the United Kingdom or in a member State, has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012(a),
- (b) in relation to a vaccine authorised for supply in a relevant country listed in the table in paragraph (2) other than a member State, means a marketing authorisation granted by the relevant regulator for the country,

“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012,

“NHS COVID pass” means the COVID-19 records available on the NHS smartphone app developed and operated by the Secretary of State, through NHS.uk or in a COVID-19 post-vaccination status letter obtained from the NHS,

“NHS England” means the health service continued under section 1(1) of the National Health Service Act 2006(b),

“NHS Scotland” means the health service continued under section 1(1) of the National Health Service (Scotland) Act 1978(c),

“NHS Wales” means the health service continued under section 1(1) of the National Health Service (Wales) Act 2006(d),

“North American Certificate” means, in relation to a state, district or province listed in the table in paragraph (6), the certificate identified in the corresponding row of the second column of that table,

“relevant country” means a country, territory or part of a country or territory listed in the first column of the table in paragraph (2) or a country, territory or part of a country or territory listed in schedule 1A (relevant countries),

“relevant regulator”, in relation to a relevant country listed in the table in paragraph (2), means the regulator identified in the corresponding row of the second column of the table in paragraph (2), and a reference to a regulator in that table is a reference to the regulatory authority of that name designated as a Stringent Regulatory Authority by the World Health Organisation pursuant to the operation of the COVAX Facility(e),

“United Kingdom vaccine roll-out overseas” means the administration of vaccine against coronavirus to—

- (a) Crown servants, government contractors or other personnel posted or based overseas and their dependants under the scheme known as the Foreign, Commonwealth and Development Office staff COVID-19 vaccination programme, or
- (b) military or civilian personnel, government contractors and their dependants at a military posting overseas, including the British overseas territories, the Channel Islands and the Isle of Man, under the vaccination scheme provided or approved by the UK Defence Medical Services,

“vaccine certificate” in relation to a passenger (“P”), means a certificate in English, French or Spanish issued by the competent health authority of a relevant country, other than a European country listed in the table in paragraph (2) or the United States of America, which contains—

- (a) P’s full name,
- (b) P’s date of birth,

---

(a) S.I. 2012/1916 was relevantly amended by S.I. 2019/775.

(b) 2006 c. 41; section 1 was substituted by the Health and Social Care Act 2012 (c. 7), section 1.

(c) 1978 c. 29.

(d) 2006 c. 42.

(e) A list of the national regulatory authorities designated as Stringent Regulatory Authorities has been published by the World Health Organization and is available online at [Product-Eligibility\\_COVAX-Facility\\_Dec2020\\_0.pdf](#) (who.int).

- (c) the name and manufacturer of the vaccine that P received,
- (d) the date that P received each dose of the vaccine, and
- (e) details of either the identity of the issuer of the certificate or the country of vaccination, or both,

“WHO List vaccine” means a vaccine which is—

- (a) listed in lines 10, 11 or 13 of the Guidance Document “Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process” published by the World Health Organisation on 11 November 2021<sup>(a)</sup>, and
- (b) authorised or certified in a country or territory, or part of a country or territory, listed in schedule 1A.

(2) The table referred to in the definitions of “relevant country” and “relevant regulator” follows—

<i>Relevant country</i>	<i>Relevant regulator</i>
a member State	European Medicines Agency
Andorra	European Medicines Agency
Australia	The Therapeutic Goods Administration
Canada	Health Canada
Iceland	European Medicines Agency
Liechtenstein	European Medicines Agency
Monaco	European Medicines Agency
Norway	European Medicines Agency
San Marino	European Medicines Agency
Switzerland	Swissmedic
the United States of America	United States Food and Drug Administration
Vatican City State	European Medicines Agency

(3) Where a course of doses of an authorised vaccine or of a WHO List vaccine has been administered to a person (“P”) by a person acting on behalf of the United Nations and authorised to administer the vaccination in that capacity, P is to be treated as if they have received those doses in a relevant country listed in schedule 1A, and any reference to doses received in a relevant country, or to the competent health authority of a relevant country in these Regulations is to be construed as a reference to doses administered by the United Nations, and to the person acting on behalf of the United Nations.

(4) For the purposes of this Part, a child is to be treated as making a declaration on the Passenger Locator Form, and possessing any evidence required, if that declaration is made, and that evidence possessed, by a person who is travelling with, and has responsibility for, that child.

(5) For the purpose of this Part the following countries and territories are approved third countries or territories—

- Albania,
- Armenia,
- Faroe Islands,
- Israel,
- Morocco,
- North Macedonia,
- Panama,

(a) [https://extranet.who.int/pqweb/sites/default/files/documents/Status\\_COVID\\_VAX\\_11Nov2021.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_11Nov2021.pdf)

Turkey,  
Ukraine.

(6) The table referred to in the definition of “North American Certificate” in paragraph (2) follows—

<i>State, District or Province</i>	<i>Certificate Name</i>
California	Digital COVID-19 Vaccine Record
New York	Excelsior Pass Plus
Washington State	WA Verify

### **Eligible vaccinated arrivals**

**3A.** A person (“P”) is an eligible vaccinated arrival if P—

- (a) is not a red list arrival, and
- (b) meets any of the descriptions in regulations 3B to 3H.

### **Eligible vaccinated arrivals: vaccination conditions**

**3B.**—(1) P meets the conditions of this regulation if P—

- (a) has completed a course of doses of an authorised vaccine or a WHO List vaccine with the final dose having been received before the start of the period beginning with the 14th day before the date of P’s arrival in Scotland,
- (b) is able to provide proof, if requested to do so by an immigration officer or the operator of the relevant service on which P travels to Scotland, of meeting the requirement in sub-paragraph (a), through—
  - (i) certification in paper or electronic form issued by NHS Scotland, or equivalent certification issued by NHS England, NHS Wales or the Department of Health in Northern Ireland, including through the NHS COVID pass,
  - (ii) the EU Digital COVID certificate,
  - (iii) the Centers for Disease Control and Prevention vaccination card,
  - (iv) a vaccine certificate,
  - (v) a North American Certificate, or
  - (vi) a certificate of COVID-19 records issued by an approved third country or territory, and
- (c) has declared on P’s Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.

(2) For the purposes of this regulation—

- (a) P has completed a course of doses if P has received the complete course of doses specified—
  - (i) in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine or a WHO List vaccine, as the case may be, or
  - (ii) in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc.) of the Human Medicines Regulations 2012 for the authorised vaccine,
- (b) if P has received a dose of one authorised vaccine or one WHO List vaccine and a dose of a different authorised vaccine or WHO List vaccine, P is deemed to have completed a course of doses of an authorised vaccine.

### **Eligible vaccinated arrivals: UK clinical trial conditions**

**3C.** P meets the conditions of this regulation if P—

- (a) has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004(a),
- (b) is able to provide proof of such participation if requested to do so by an immigration officer or the operator of the relevant service on which P travels to Scotland, and
- (c) has declared on P's Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.

### **Eligible vaccinated arrivals: US clinical trial conditions**

**3D.** P meets the conditions of this regulation if P—

- (a) has participated or is participating in a clinical trial regulated in the United States of America by the Food and Drugs Administration of a vaccine for vaccination against coronavirus,
- (b) is able, if requested to do so by an immigration officer or the operator of the relevant service on which P travels to Scotland, to provide proof of such participation through the Centers for Disease Control and Prevention vaccination card, and
- (c) has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.

### **Eligible vaccinated arrivals: Non-UK or US clinical trial conditions**

**3E.—**(1) P meets the conditions of this regulation if P—

- (a) has participated, or is participating in, phase 2 (therapeutic exploratory studies) or phase 3 (clinical efficacy and safety studies) of a clinical trial of a vaccine for vaccination against coronavirus which is regulated by—
  - (i) the European Medicines Agency, or
  - (ii) a regulatory authority (other than such an authority in the United Kingdom or the United States of America) which is designated as a Stringent Regulatory Authority by the World Health Organization(b),
- (b) is able, if requested to do so by an immigration officer or the operator of the relevant service on which P travels to Scotland, to provide proof of such participation through a participation document, and
- (c) has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.

(2) For the purposes of this regulation, “participation document” means a document in English, French or Spanish issued by a relevant person which confirms—

- (a) P's full name,
- (b) P's date of birth,
- (c) the name and manufacturer of the vaccine,
- (d) the country or territory in which the clinical trial is taking, or took, place,
- (e) the regulatory authority responsible for the regulation of the clinical trial,

---

(a) S.I. 2004/1031, to which there are amendments not relevant to these Regulations.

(b) The current list national regulators designated as Stringent Regulatory Authorities is available here: <https://www.who.int/initiatives/who-listed-authority-reg-authorities/SRAs>.

- (f) the phase of the clinical trial in which P is participating or participated.
- (3) For the purposes of paragraph (2) “relevant person” means—
  - (a) the competent health authority of the country or territory in which the relevant clinical trial is being, or was, carried out, or
  - (b) the person who is conducting, or conducted, the relevant clinical trial.

**Eligible vaccinated arrivals: UK clinical exemptions conditions**

- 3F.** P meets the conditions of this regulation if P—
- (a) is a person who cannot be vaccinated against coronavirus for medical reasons with an authorised vaccine or a WHO List vaccine,
  - (b) is able to provide proof of that if requested to do so by an immigration officer or the operator of the relevant service on which P travels to Scotland, and
  - (c) has declared on P’s Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.

**Eligible vaccinated arrivals: age conditions**

**3G.** P meets the conditions of this regulation if P is under the age of 18 years upon arrival in Scotland.

**Eligible vaccinated arrivals: UK vaccine rollout overseas conditions**

- 3H.**—(1) P meets the conditions of this regulation if P is either—
- (a) a person who—
    - (i) has completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas, with the final dose having been received before the start of the period beginning with the 14th day before the date of P’s arrival in Scotland,
    - (ii) is able to provide proof, if requested to do so by an immigration officer or the operator of the relevant service on which P travels to Scotland, of meeting the requirement in head (i), and
    - (iii) has declared on P’s Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.
- (2) For the purposes of this regulation—
- (a) P has completed a course of doses of a vaccine if P has received the complete course of doses specified—
    - (i) in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine or a WHO List vaccine, as the case may be, or
    - (ii) in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc.) of the Human Medicines Regulations 2012 for the authorised vaccine or WHO List vaccine,
  - (b) where P has received a dose of an authorised vaccine or WHO List vaccine and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas,
  - (c) where P has received a dose of one vaccine under the United Kingdom vaccine roll-out overseas, and a dose of a different vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas.

(3) Where P is a person described in paragraph (2)(b), the proof which P provides for the purposes of paragraph (1)(a)(ii) must include proof of having received the dose of an authorised vaccine or WHO List vaccine through—

- (a) certification in paper or electronic form issued by NHS Scotland, or equivalent certification issued by NHS England, NHS Wales or the Department of Health in Northern Ireland, including through the NHS COVID pass,
- (b) the EU Digital COVID certificate,
- (c) the Centers for Disease Control and Prevention vaccination card,
- (d) a vaccine certificate,
- (e) a North American Certificate,
- (f) a certificate of COVID-19 records issued by an approved third country or territory.”.

#### **Amendment of regulation 6**

**5.** In regulation 6 (Part 2: persons not required to comply)—

- (a) after paragraph (1)(b), insert—
  - “(ba) a person who, on arrival in the United Kingdom, passes through to another country or territory outside the common travel area without entering the United Kingdom,”,
- (b) in paragraph (1)(c)—
  - (i) in head (i), omit “or” at the end,
  - (ii) after head (ii), insert—
    - “, or
    - (iii) paragraph 15 (road haulage worker),”,
- (c) in paragraph (1)(e)—
  - (i) in the opening text, after “in”, insert “any”,
  - (ii) for head (ii) substitute—
    - “(ii) paragraph 9(1) and (2) (seamen and masters etc.) who has travelled to the United Kingdom on a vessel in the course of their work,
    - (iia) paragraph 9(3) (inspector or surveyor of ships),”,
    - (iii) omit “, where the condition in paragraph 16 of that schedule is met”,
- (d) for paragraph (2), substitute—
  - “(2) Paragraph (1)(b) and (c)(i) do not apply where P is a red list arrival in the case of a person described in paragraphs 1(1) of schedule 4.”.

#### **Amendment of regulation 7**

**6.** In regulation 7(2)(b)(i) (Part 3: interpretation) for “Covid” substitute “COVID”.

#### **Amendment of regulation 14**

**7.** In regulation 14 (requirement to undertake tests)—

- (a) for paragraph (9A) substitute—
  - “(9A) For the purposes of paragraph (9)(b), a test complies with this paragraph if—
    - (a) it is a semi-quantitative test for the detection of coronavirus which—
      - (i) targets a minimum of two distinguishable SARS-CoV-2 genes other than the S gene and performance reference controls,
      - (ii) includes routine in silico assurance against every variant of concern, and



- (iii) produces a test solution that provides extracted nucleic acid that is suitable for whole genome sequencing using a specified method,
- (b) it is, in relation to a red list arrival, a test that can be self-administered,
- (c) the manufacturer of any device used for the purposes of the test states that the device—
  - (i) uses an established molecular detection method,
  - (ii) in relation to a day 2 test, has a specificity and a sensitivity greater than or equal to 99% (or a 95% two-sided confidence interval entirely above 97%),
  - (iii) in relation to a day 8 test, has a specificity greater than or equal to 97% (or a 95% two-sided confidence interval entirely above 95%),
  - (iv) in relation to a day 8 test, has a sensitivity greater than or equal to 95% (or a 95% two-sided confidence interval entirely above 90%),
  - (v) has a limit of detection of less than or equal to 1000 SARS-CoV-2 copies per millilitre, and
  - (vi) is suitable for identifying every variant of concern, and
- (d) any device used for the purposes of the test—
  - (i) can be put into service in accordance with Part 4 of the Medical Devices Regulations 2002(a), other than solely by virtue of regulation 39(2) of those Regulations, and
  - (ii) has been validated no more than 18 months before the test is administered or provided to P.”,
- (b) after paragraph (11), insert—
  - “(12) For the purposes of paragraph (9A)—
    - (a) “specified method” means a targeted sequence method specific to SARS-CoV-2 or an equivalent—
      - (i) amplicon method, or
      - (ii) sequence bait capture method,
    - (b) “validated”, in relation to a device, means confirmed as having the required sensitivity and specificity using at least 150 positive clinical samples and 250 negative clinical samples against a laboratory-based RT-PCR test that is itself within the performance specification of the target product profile published by the Medicines and Healthcare Products Regulatory Agency for laboratory based SARS-CoV-2 PCR tests, by—
      - (i) the Secretary of State, or
      - (ii) a laboratory which is accredited to ISO standard 15189 or ISO/IEC standard 17025(b) by—
        - (aa) the United Kingdom Accreditation Service(c), or

---

(a) S.I. 2002/618, relevantly amended by S.I. 2019/791 and S.I. 2020/1478.

(b) ISO standards are published in Geneva by the International Organisation for Standardisation, and are available on their website ([www.iso.org](http://www.iso.org)) or at ISO Central Secretariat, International Organization for Standardization (ISO), 1 rue de Varembe, Case postale 56, CH-1211, Geneva 20, Switzerland. ISO 15189 Medical Laboratories requirements for quality and competence was published in November 2012. ISO/IEC 17025 General requirements for the competence of testing and calibration laboratories was published in November 2017.

(c) The United Kingdom Accreditation Service is a company limited by guarantee incorporated in England and Wales under number 3076190.

- (bb) an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation (“ILAC”) Mutual Recognition Arrangement<sup>(a)</sup> or the European co-operation for Accreditation (“EA”) Multilateral Agreement<sup>(b)</sup>,
  - other than a laboratory which processes tests provided by the test provider for the purposes of this Part or which is owned by the test provider or the device manufacturer<sup>(c)</sup>,
- (c) “variant of concern” means a variant of SARS-CoV-2 identified in a designation published by the UK Health Security Agency for the purposes of this paragraph<sup>(d)</sup>.”.

#### **Amendment of regulation 18**

**8.** In regulation 18 (Part 4: persons not required to comply)—

(a) for paragraph (1)(d), substitute—

“(d) a person who, on arrival in the United Kingdom—

- (i) passes through to another country or territory outside the common travel area without entering the United Kingdom, or
- (ii) enters the United Kingdom for the sole purpose of continuing a journey to a country or territory outside the common travel area and—
  - (aa) remains within their port of entry until their departure from Scotland, or
  - (bb) travels directly from their port of entry to another port of departure in Scotland.”.

#### **Amendment of regulation 27**

**9.** In regulation 27 (Part 6: persons not required to comply)—

(a) for paragraph (1)(c) substitute—

“(c) a person who, on arrival in the United Kingdom—

- (i) passes through to another country or territory outside the common travel area without entering the United Kingdom, or
- (ii) enters the United Kingdom for the sole purpose of continuing a journey to a country or territory outside the common travel area and—
  - (aa) remains within their port of entry until their departure from Scotland, or
  - (bb) travels directly from their port of entry to another port of departure in Scotland.”.

(b) in paragraph (1)(ca) after “age of 11,” insert “and”.

#### **Amendment of schedule 1A**

**10.** In schedule 1A (relevant countries), in the appropriate places in alphabetical order insert—

“Belarus”,

“British Antarctic Territory”,

- 
- (a) ILAC is an international organisation which coordinates the work of its signatory national accreditation bodies which are themselves involved in the accreditation of conformity assessment bodies, testing laboratories, and medical testing laboratories.
  - (b) EA is a regional organisation which coordinates the work of its signatory national accreditation bodies. EA is recognised by and works closely with ILAC.
  - (c) A body corporate established under section 232 of the Health and Social Care Act 2012 (c. 7).
  - (d) Technical briefing documents on novel SARS-CoV-2 variants are published by the UK Health Security Agency and are available online at <https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings>.

“British Indian Ocean Territory”,  
“British Virgin Islands”,  
“Bolivia”,  
“Democratic Republic of the Congo”,  
“Dominican Republic”,  
“Ecuador”,  
“Falkland Islands”,  
“Guernsey”,  
“Isle of Man”,  
“Jersey”,  
“Laos”,  
“Libya”,  
“Malawi”,  
“Montserrat”,  
“Mozambique”,  
“Pitcairn, Henderson, Ducie and Oeno Islands”,  
“Saint Helena, Ascension and Tristan da Cunha”,  
“Samoa”,  
“Senegal”,  
“South Georgia and the South Sandwich Islands”,  
“The Sovereign Base Areas of Akrotiri and Dhekelia in the Island of Cyprus”,  
“Turks and Caicos Islands”,  
“Vanuatu”,  
“Zambia”,  
“Zimbabwe”.

### **Amendment of schedule 3**

**11.** For paragraph 5 of schedule 3 (passenger information), substitute—

“5. Where the passenger is an eligible vaccinated arrival, a declaration that the passenger meets the COVID-19 vaccination eligibility criteria.”.

### **Amendment of schedule 6**

**12.** In Part 1 of schedule 6 (specified competitions), after paragraph 38A(a), insert—

“**38B.** Netball – international netball fixtures for the Scottish Thistles Netball Team.”.

### **Amendment of schedule 8**

**13.** In schedule 8 (passenger notices), in the paragraph headed “Unvaccinated passengers or vaccinated passengers with unauthorised vaccines”, in the sentence numbered 2, for “compete” substitute “complete”.

---

(a) Paragraph 38A was inserted by S.S.I. 2021/350.

## **Savings and transitional provisions**

**14.** Subject to regulation 15, the amendments made by these Regulations do not apply in relation to any person who arrived in Scotland before 17 December 2021, and the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Regulations 2021 continue to apply to such persons as if the amendments made by these Regulations had not been made.

**15.** Anything done or required to be done under the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Regulations 2021 as amended by the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Amendment (No. 7) Regulations 2021 (the “Amendment No. 7 Regulations”) which would, but for the expiry of the Amendment No. 7 Regulations, have had effect on and after 17 December 2021 is deemed to have been done or required to be done under the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Regulations 2021 as amended by these Regulations.

St Andrew’s House,  
Edinburgh  
16th December 2021

*MICHAEL MATHESON*  
A member of the Scottish Government

## EXPLANATORY NOTE

*(This note is not part of the Regulations)*

These Regulations amend the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Regulations 2021 (“the International Travel Regulations”) to re-introduce amendments previously made by the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Amendment (No. 7) Regulations 2021 (the “Amendment No. 7 Regulations”) which expired on 15 December 2021.

Regulation 4 re-introduces the previous Part 1A and consolidates the previous regulation 3 of the International Travel Regulations, with amendments, which—

- expand the definition of “authorised vaccine” by removing the requirement that it be administered in a relevant country (new regulation 3);
- extend the scope of the scheme to recognise WHO emergency use vaccines;
- insert a new definition of EU Digital Covid Certificate;
- amend provision regarding the proof which may be provided of vaccination status in order to recognise certain certificates issued by a State or District of the USA;
- require persons vaccinated against coronavirus in Guernsey, Jersey, the Isle of Man or any of the United Kingdom Overseas Territories, and their dependents, to satisfy the conditions in new regulation 3B, rather than the conditions in new regulation 3H which apply in relation to the UK vaccine rollout overseas;
- expand the categories of “eligible vaccinated arrival” to include individuals who have participated, or are participating, in phase 2 or 3 of certain clinical trials taking place otherwise than in the United Kingdom or the United States of America (new regulation 3E);
- provide that the clinical exemptions which apply in relation to eligible vaccinated arrivals apply to persons who cannot be vaccinated against coronavirus for medical reasons (new regulation 3F);
- expand the scope of the eligible vaccinated arrival scheme so that all children under the age of 18 will be categorised as eligible, irrespective of vaccine status (new regulation 3G).

Regulation 3 makes consequential amendments following the insertion of new Part 1A.

Regulation 5 amends again the exemptions from the requirement to complete a Passenger Locator Form for certain persons who have travelled to the UK. For persons travelling in the course of their work as a road passenger transport worker, seamen and masters (if travelling to the UK on a vessel in the course of their work), inspectors and surveyors of ships, aircraft crew, and tunnel system transport workers, the exemption will apply whether or not they have been in a red list country or travelled in a passenger carrying conveyance. New exemptions are inserted for passengers transiting through the UK and road haulage workers.

Regulation 7 updates the requirements of the type of test to be taken by persons following their arrival in Scotland.

Regulations 8 and 9 re-amend regulations 18 and 27 of the International Travel Regulations respectively. For the purposes of exemption from Part 4 (testing following arrival in Scotland) and Part 6 (self-isolation) of those Regulations, a person who on arrival in the UK travels onward to another country or territory without passing through border control into the UK are exempt, as well as persons who pass through the border into the UK for the sole purpose of continuing a journey to a country or territory outside the common travel area.

Regulation 10 adds to the list of countries which are “relevant countries” so persons who have a vaccine certificate from those countries can count as “eligible vaccinated arrivals” for the purposes of the International Travel Regulations.

Regulation 11 makes consequential amendments to the passenger information specified in schedule 3 of the International Travel Regulations.

Regulation 12 adds international netball fixtures for the Scottish Thistles Netball Team to the specified competitions in relation to which elite sportspersons (defined in paragraph 42 of schedule 4 of the International Travel Regulations) may be exempt from certain requirements for testing and self-isolation (see regulations 25(1)(e) and 27(1)(h) of the International Travel Regulations).

Regulation 13 corrects a minor printing error introduced into the International Travel Regulations by the Health Protection (Coronavirus) (International Travel and Operator Liability) (Scotland) Amendment (No. 12) Regulations 2021.

Regulation 14 makes savings provision to the effect that a person arriving in Scotland before these Regulations come into effect must comply with the International Travel Regulations as they had effect at the time of the person's arrival in Scotland. The amendments made by these Regulations apply only in relation to persons arriving in Scotland at or after 17 December 2021.

Regulation 15 makes savings provision to the effect that anything done or required to be done under the International Travel Regulations as amended by the Amendment No. 7 Regulations which, but for the expiry of the Amendment No. 7 Regulations, would still have had effect on or after the coming into force of these Regulations, is deemed to have been done or required to be done under the International Travel Regulations as amended by these Regulations.

An impact assessment was prepared and has been published online at [www.legislation.gov.uk](http://www.legislation.gov.uk) for the Amendment No. 7 Regulations. These Regulations have like effect.

The previous Regulations amending the International Travel Regulations were incorrectly titled the Public Health (Coronavirus) (International Travel and Operator Liability) (Scotland) Amendment (No. 13) Regulations 2021 (S.S.I. 2021/470), therefore these Regulations are titled "(No. 13)" in the series of amendment Regulations rather than "(No. 14)".

---

© Crown copyright 2022


Printed and published in the UK by The Stationery Office Limited under the authority and superintendence of Jeff James, the Queen's Printer for Scotland.



£6.90

<http://www.legislation.gov.uk/id/ssi/2021/478>

ISBN 978-0-11-105342-3



9 780111 053423